Danish pharmaceutical company Novo Nordisk on Wednesday signed a memorandum of understanding with Eskayef Pharmaceuticals Ltd of Bangladesh for state-of-the-art technology transfer for advanced insulin manufacturing,  says a press release. “As part of our continuous commitment for people living with diabetes in Bangladesh, we have decided to set-up local manufacturing of insulin for advanced pens in partnership with Eskayef,” said Sebnem Avsar Tuna, corporate vice president of the company’s business area Oceania and South East Asia, at a ceremony held to mark the signing of the MoU at a hotel in the capital. Under this agreement, for the first time ever Danish advanced technology for manufacturing state-of-the-art insulin devices of Novo Nordisk will be undertaken outside of Denmark.